The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder.

Issued July 25, the new US patent gives Enveric IP rights for compositions and methods for tryptamine-derived prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives. 

The company holds that these enhancements to the tryptamine chemical structure could provide a more rapid onset of action, more controlled therapeutic effect and reduced gastrointestinal side-effects compared to traditional psilocin prodrugs like psilocybin. 

Enveric’s director and CEO Dr. Joseph Tucker poses that, while several tryptamines -including psilocybin, DMT and 5-MeO-DMT- “have shown therapeutic benefit for the treatment …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.